

# Literatura

- Adam R, Chiche L, Aloia T, et al.; the Association Française de Chirurgie. Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1452 patients and development of a prognostic model. *Ann Surg* 2006;244:524–535.
- Akahoshi K, Oya M, Koga T, et al. Current clinical management of gastrointestinal stromal tumor. *World J Gastroenterol* 2018;24:2806–2817.
- Auer RC, Sivajohanathan D, Biagi J, et al. Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a clinical practice guideline. *Curr Oncol* 2020;27:146–154.
- Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell* 2004;116:281–297.
- Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018;68:394–424.
- Büchler T, et al. *Obecná onkologie*. Praha: Maxdorf, 2019.
- Cardoso F, Senkus E, Costa A, et al. 4<sup>th</sup> ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4). *Ann Oncol* 2018;29:1634–1657.
- Casali PG, Abecassis N, Aro HT, et al. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2018;29(Suppl 4):iv267.
- Caswell-Jin JL, Plevritis SK, Tian L, et al. Change in survival in metastatic breast cancer with treatment advances: meta-analysis and systematic review. *JNCI Cancer Spectr* 2018;2:062.
- Charville GW, Longacre TA. Surgical pathology of gastrointestinal stromal tumors: practical implications of morphologic and molecular heterogeneity for precision medicine. *Adv Anat Pathol* 2017;24:336–353.
- Chen K, Zhou YC, Mou YP, et al. Systematic review and meta-analysis of safety and efficacy of laparoscopic resection for gastrointestinal stromal tumors of the stomach. *Surg Endosc* 2015;29:355–367.
- Coe TM, Fero KE, Fanta PT, et al. Population-based epidemiology and mortality of small malignant gastrointestinal stromal tumors in the USA. *J Gastrointest Surg* 2016;20:1132–1140.
- Conroy T, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. *N Engl J Med* 2018;379:2395–2406.
- Conroy T, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. *N Engl J Med* 2011;364:1817–1825.
- Crabtree JS, Singleton CS, Miele L. Notch signaling in neuroendocrine tumors. *Front Oncol* 2016;6:94.
- Demes M, Aszyk C, Bartsch H, et al. Differential miRNA-expression as an adjunctive diagnostic tool in neuroendocrine tumors of the lung. *Cancers (Basel)* 2016;8:38.
- Demetri GD, Wang Y, Wehrle E, et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. *J Clin Oncol* 2009;27:3141–3147.
- Duda M, Ryska M, Žaloudík J, et al. *Onkochirurgie v České republice*. *Rozhl Chir* 2020;99:521–528.
- Engstrand J, Nilsson H, Strömberg C, et al. Colorectal cancer liver metastases - a population-based study on incidence, management and survival. *BMC Cancer* 2018;18:78.
- Fernandez-Cuesta L, Plenker D, Osada H, et al. CD74-NRG1 fusions in lung adenocarcinoma. *Cancer Discov* 2014;4:415–422.

- Ferreri AJM, Holdhoff M, Nayak L, Rubenstein JL. Evolving treatments for primary central nervous system lymphoma. *Am Soc Clin Oncol Educ Book* 2019;39:454–466.
- Fox BD, Cheung VJ, Patel AJ, et al. Epidemiology of metastatic brain tumors. *Neurosurg Clin N Am* 2011;22:1–6.
- Fox CP, Phillips EH, Smith J, et al. British Society for Haematology guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma. *Br J Haematol* 2019;184:348–363.
- Garajová I, Funel N, Fiorentino M, et al. MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma – a step towards personalized therapy. *Clin Epigenetics* 2015;7:129.
- George J, Lim JS, Jang SJ, et al. Comprehensive genomic profiles of small cell lung cancer. *Nature* 2015;524:47–53.
- Golan T, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. *N Engl J Med* 2019;381:317–327.
- Goldstraw P, Ball D, Jett JR, et al. Non-small-cell lung cancer. *Lancet* 2011;378:1727–1740.
- Guinney J, Dienstmann R, Wang X, De Reynies A, et al. The consensus molecular subtypes of colorectal cancer. *Nat Med* Nov 2015;21:1350–1356.
- Hatipoğlu E. Extragastrintestinal stromal tumor (EGIST): A 16-year experience of 13 cases diagnosed at a single center. *Med Sci Monit* 2018;24:3301–3306.
- Heald RJ, Santiago I, Pares O, et al. The perfect total mesorectal excision obviates the need for anything else in the management of most rectal cancers. *Clin Colon Rectal Surg* 2017;30:324–332.
- Hoskovec D, Krška Z, Vočka M, et al. PIPAC – přehled metody a první použití v České republice. *Rozhl Chir* 2020;99:529–533.
- Inamura K, Ishikawa Y. MicroRNA in lung cancer: novel biomarkers and potential tools for treatment. *J Clin Med* 2016;5:36.
- Inamura K, Ninomiya H, Ishikawa Y, Matsubara O. Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features? *Arch Pathol Lab Med* 2010;134:66–72.
- Inamura K, Satoh Y, Okumura S, et al. Pulmonary adenocarcinomas with enteric differentiation: histologic and immunohistochemical characteristics compared with metastatic colorectal cancers and usual pulmonary adenocarcinomas. *Am J Surg Pathol* 2005;29:660–665.
- Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. *J Thorac Oncol* 2008;3:13–7.
- Inamura K. Karcinom plic: porozumění jeho molekulární patologii a klasifikace WHO 2015. *Front Oncol* 2017;7:19.
- Joensuu H, Wardelmann E, Sihto H, et al. Effect of KIT and PDGFRA mutations on survival in patients with gastrointestinal stromal tumors treated with adjuvant imatinib: an exploratory analysis of a randomized clinical trial. *JAMA Oncol* 2017;3:602–609.
- Kala Z, Procházka V, Grolich T, et al. Moderní trendy v chirurgii kolorektálního karcinomu. *Onkologie* 2017;11:54–60.
- Katz MHG, Shi Q, Meyers J, et al. Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas. *JAMA Oncol* 2022;8:1263–1270.
- Ke H, Kazi JU, Zhao H, Sun J. Germline mutations of KIT in gastrointestinal stromal tumor (GIST) and mastocytosis. *Cell Biosci* 2016;6:55.
- Klener P jr., Klener P. Principy systémové protinádorové léčby. Praha: Grada, 2013.
- Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung adenocarcinoma. *Nat Med* 2012;18:375–377.

Krška Z, Hoskovec D, Petruželka L, et al. Chirurgická onkologie. Praha: Grada, 2014.

Lassman AB, DeAngelis LM. Brain metastases. *Neurol Clin* 2003;21:1–23.

Leone, JP, Leone BA. Breast cancer brain metastases: the last frontier. *Exp Hematol Oncol* 2015;4:33.

#### Literatura

Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. *Neuro-Oncology* 2021;23:1231–1251.

Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. *Nature* 2005;435:834–838.

Luke JJ, Flaherty KT, Ribas A, et al. Targeted agents and immunotherapies: Optimizing outcomes in melanoma. *Nat Rev Clin Oncol* 2017;14:463–482.

Martin-Tellez KS, van Houdt WJ, van Coevorden F, et al. Isolated limb perfusion for soft tissue sarcoma: Current practices and future directions. A survey of experts and a review of literature. *Cancer Treat Rev* 2020;88:102058.

Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. *Arch Pathol Lab Med* 2006;130:1466–1478.

Mise Y, Aloia TA, Brudvik KW, et al. Parenchymal-sparing hepatectomy in colorectal liver metastasis improves salvageability and survival. *Ann Surg* 2016;263:146–152.

Nadal E, Zhong J, Lin J, et al. A microRNA cluster at 14q32 drives aggressive lung adenocarcinoma. *Clin Cancer Res* 2014;20:3107–3117.

Nakaoku T, Tsuta K, Ichikawa H, et al. Druggable oncogene fusions in invasive mucinous lung adenocarcinoma. *Clin Cancer Res* 2014;20:3087–3093.

National Comprehensive Cancer Network. National Comprehensive Cancer Network Guidelines 01/2021 – Gastrointestinal Stromal Tumors [online].  
Dostupné z: [https://www.nccn.org/professionals/physician\\_gls/pdf/gist.pdf](https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf)

Nelson H, Petrelli N, Carlin A, et al. Guidelines 2000 for colon and rectal cancer surgery. *J Natl Cancer Inst* 2001;93:583–596.

Neoptolemos JP, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. *Lancet* 2017;389:1011–1024.

Ninomiya H, Hiramatsu M, Inamura K, et al. Correlation between morphology and EGFR mutations in lung adenocarcinomas significance of the micropapillary pattern and the hobnail cell type. *Lung Cancer* 2009;63:235–240.

Novotný J, Vítek P, et al. Onkologie v klinické praxi. Praha: Mladá fronta, 2012.

Onitilo AA, Engel JM, Stankowski RV, et al. Survival comparisons for breast conserving surgery and mastectomy revisited: community experience and the role of radiation therapy. *Clin Med Res* 2015;13:65–73.

Pasini B, McWhinney SR, Bei T, et al. Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. *Eur J Hum Genet* 2008;16:79–88.

Peifer M, Fernandez-Cuesta L, Sos ML, et al. Integrační analýzy genomu identifikují klíčové somatické řídicí mutace malobuněčného karcinomu plic. *Nat Genet* 2012;44:1104–1110.

Peifer M, Fernandez-Cuesta L, Sos ML, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. *Nat Genet* 2012;44:1104–1110.

Peter Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. *N Engl J Med* 2020;382:810–821.

- Reiss KA, Mick R, Teitelbaum U, et al. Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial. *Lancet Oncol* 2022;23:1009–1020.
- Rudin CM, Durinck S, Stawiski EW, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. *Nat Genet* 2012;44:1111–1116.
- Sabel MS, Diehl KM, Chang AE. Principles of surgical therapy in oncology. In: *Oncology – An Evidence-Based Approach*. New York, NY; Springer 2006.
- Sandru A, Voinea S, Panaitescu E, Blidaru A. Survival rates of patients with metastatic malignant melanoma. *J Med Life* 2014;7:572–576.
- Šašková P, Pavlišta D, Dostálek L. Spokojenost a celková kvalita života BRCA pozitivních žen po profylaktických výkonech. *Rozhl Chir* 2017;96:328–333.
- Schulz MS. Anti-EGFR reintroduction and rechallenge in metastatic colorectal cancer (mCRC): a real-world analysis. *Cancers* 2022;14:1641.
- Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. *J Clin Oncol* 2009;27:4247–4253.
- Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. *J Natl Cancer Inst* 2005;97:339–346.
- Shim HS, Kenudson M, Zheng Z, et al. Unique genetic and survival characteristics of invasive mucinous adenocarcinoma of the lung. *J Thorac Oncol* 2015;10:1156–1162.
- Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. *CA Cancer J Clin* 2014;64:104–117.
- Stewart CL, Warner S, Ito K, et al. Cytoreduction for colorectal metastases: liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure? *Curr Probl Surg* 2018;55:330–379.
- Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. *JAMA* 2017;318:2306–2316.
- Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. *Nat Med* 2012;18:378–381.
- The Cancer Gene Atlas Research Network. Komplexní molekulární profilování adenokarcinomu plic. *Nature* 2014;511:543–550.
- The Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. *Nature* 2012;489:519–525.
- The Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. *Nature* 2014;511:543–550.
- Tsuta K, Kohno T, Yoshida A, et al. RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis. *Br J Cancer* 2014;110:1571–1578.
- Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. *N Engl J Med* 2021;384:2394–2405.
- Ústav zdravotnických informací a statistiky ČR. Národní onkologický registr, 2018 [online]. Dostupné z: <http://www.uzis.cz/res/novotvary2018.pdf>
- Ústav zdravotnických informací a statistiky ČR. TNM klasifikace zhoubných nádorů, 7. vydání 2009, česká verze 2011, aktualizace 2017 [online]. Dostupné z: <https://www.uzis.cz/index.php?pg=registry-sber-dat--klasifikace--tnm-klasifikace-zhoubnych-novotvaru>
- Vaishnavi A, Capelletti M, Le AT, et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. *Nat Med* 2013;19:1469–1472.
- Veronesi U, Paganelli G, Galimberti V, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. *Lancet* 1997;349:1864–1867.

Vítek P, Zeman K, Mikoviny Kajzrlíková I. Kolorektální karcinom-současný stav léčby. Interní Med 2012;14:250–252.

Vočka M, Špaček M, Matějovský Z, et al. Neoadjuvantní užití hypertermické izolované perfuze končetiny v léčbě nediferencovaného vřetenobuněčného sarkomu dolní končetiny s dosažením kompletní patologické odpovědi. Klin Onkol 2019;32:211–213.

Von Baumgarten L, Illerhaus G, Korfel A, et al. The diagnosis and treatment of primary CNS lymphoma. Dtsch Arzteblatt Int 2018;115:419–426.

Von Hoff DD, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691–1703.

Vyzula R, Žaloudík J, a kol. Rakovina tlustého střeva a konečníku. Praha: Maxdorf, 2007.

Wang-Gillam A, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 2016;387:545–557.

Wyld L, Audisio RA, Poston GJ. The evolution of cancer surgery and future perspectives. Nat Rev Clin Oncol 2015;12:115–124.

Yang J, Du XL, Li ST, et al. Characteristics of differently located colorectal cancers support proximal and distal classification: a population-based study of 57,847 patients. PLoS One 2016;11:e0167540.

Yoshida A, Kohno T, Tsuta K, et al. ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases. Am J Surg Pathol 2013;37:554–562.

ALM	aktinomykóza
ALI	alternativní léčba
A/C	adenomatózní polypóza
AR	androgenový receptor
ASCO	American Society of Clinical Oncology
ATL	adult T-cell leukemia/lymphoma, T-buněčná leukémie u dospělých
ATM	ataxia-telangiectasia mutated
ATP	adenosin triphosfát
ATRX	alpha thalassemia / mental retardation syndrome X-linked
BAD	BCL2 associated agonist of cell death
EANT	biologically active neuroendocrine tumor, biologicky aktivní neuroendokrinní nádor
BER	base excision repair
BINT	biologically inactive neuroendocrine tumors, biologicky neaktivní neuroendokrinní nádor
BIRC5	baculovirus inhibitor of apoptosis protein 5, survivin
BL	blastomykóza
BRAF	BRAF proto-onkogen, serin/threoninová kináza
HCCAT2	hepatocelulární karcinom
HRPC	hormonálně závislá prostatická rakovina, hranice resekabilní prostatická rakovina
CDC	Centers for Disease Control and Prevention, Centrum pro kontrolu nemocí a prevenci
CDCC	CD8+ cytotoxic T-cell mediated cytotoxicity
CDH1	cadherin 1
CDK	cyclin dependent kinase, cyklin dependentní kináza
CDKN2A	cyclin-dependent kinase inhibitor 2A
CEACAM1	carcinoembryonic antigen-related cell adhesion molecule 1